Monitor for the MHRA resubmission of tivoxavir marboxil's toxicology package by end of Q3 2026, as this is the key catalyst for the Series A warrant exercise and potential $10M capital infusion. The FDA clinical hold resolution timeline (targeted by end of 2026) is the next major binary event. Given the $9M market cap and cash runway into Q1 2027, the stock is highly sensitive to regulatory milestones and financing execution.
Price Chart
Executive Summary
Traws Pharma reported a Q2 2026 EPS of -$0.53, missing the consensus estimate of -$0.45 by 17.8%. The company had zero revenue for the quarter, compared to $2.7M in the same period last year, due to the non-recurrence of a legacy licensing agreement termination. The stock's reaction is likely muted given the pre-revenue status and the EPS miss being on a small absolute base, with focus remaining on the tivoxavir marboxil program's regulatory path and financing milestones.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.53 missed consensus of -$0.45 by 17.8%
- Zero revenue reported for Q2 2026 vs $2.7M in Q2 2025 due to non-recurring deferred revenue from a terminated licensing agreement
- Net loss widened to $3.0M from $0.9M in the prior-year quarter
- Cash and equivalents of $5.0M as of June 30, 2026, up from $3.8M at year-end 2025
- Company expects cash runway into Q1 2027 but may need additional financing thereafter
- FDA clinical hold on tivoxavir marboxil IND remains; MHRA resubmission expected by end of Q3 2026
- April 2026 private placement delivered $10M upfront with potential for up to $50M in milestone-based tranches
Financial Impact
EPS miss of 17.8% on a small absolute base (-$0.53 vs -$0.45 consensus); revenue decline to zero from $2.7M YoY due to non-recurring item
Risk Factors
- FDA clinical hold on tivoxavir marboxil may not be resolved by end of 2026
- Cash runway only into Q1 2027; additional financing needed and milestone-based tranches are contingent on program success and investor participation
- Zero revenue and widening net losses with no near-term commercialization prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345629 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3340 (+4.84%) |
Oct 20, 2026 5d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3340 (−11.17%) |
Oct 20, 2026 5d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3340 (+11.17%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3340 (+38.15%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3340 (+51.23%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3340 (+51.23%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3340 (+56.05%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3340 (−56.05%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3340 (−56.49%) |
Jun 22, 2026 18w ago | 8-K | $0.8918 $0.6710 | ▼ −24.76% | ▼ −24.61% | $0.3340 (−62.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers